Ayurvedic Local and Oral Drug Delivery Therapies in Yonikandu (Atrophic Vaginitis): Evidence from Randomized Controlled Trials.
International Journal of Drug Delivery Technology · 01.06.2026 · 16 (41s)
DOI: 10.25258/ijddt.16.41s.84 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 01.06.2026. Verfasst von Dr Hemalata V Meenkire und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Atrophic vaginitis is a common gynecological condition primarily affecting postmenopausal women due to declining estrogen levels. In Ayurvedic literature, Yonikandu is described as an independent disease entity in Madhav Nidan (Yonikandu Adhyaya), which is clinically comparable to atrophic vaginitis and is characterized by vaginal itching, dryness, and irritation. The condition is characterized by Yoni Rukshata (Vaginal dryness), itching, irritation, inflammation, and increased susceptibility to infections resulting from structural and microbial alterations in vaginal tissues. Conventional management approaches, including hormone replacement therapy, topical estrogen creams, and lubricants, may provide symptomatic relief; however, concerns regarding long-term safety, contraindications, and patient acceptability have encouraged exploration of alternative therapeutic strategies. Ayurveda offers a holistic framework for managing Yonikandu (Vaginal itching) through herbal medicines, lifestyle modifications, and localized therapeutic applications. Local drug delivery systems such as medicated oils (Taila), medicated ghee (Ghrita), herbal pastes, suppositories, and vaginal gels provide targeted therapy by enhancing lubrication, reducing inflammation, and promoting tissue healing. Oral Ayurvedic formulations including tablets, capsules, decoctions (Kwatha), and powders (Churna) contribute systemic therapeutic effects by modulating immune responses, hormonal balance, and physiological functions. Advances in herbal drug delivery technologies, including mucoadhesive gels, nanotechnology-based carriers, liposomal systems, and sustained-release formulations, further enhance therapeutic potential and drug bioavailability. Evidence from clinical studies indicates promising outcomes in symptom reduction and improvement of vaginal health. Nevertheless, further large-scale clinical trials and standardized formulations are necessary to validate efficacy and safety. Integrating Ayurvedic therapeutic principles with modern pharmaceutical technologies may offer innovative, effective, and patientcentered strategies for managing Yonikandu (Vaginal itching) and related gynecological disorders.
Zitieren
APA
Meenkire, D. H. V., & Makim, D. R. (2026). Ayurvedic Local and Oral Drug Delivery Therapies in Yonikandu (Atrophic Vaginitis): Evidence from Randomized Controlled Trials. International Journal of Drug Delivery Technology, 16(41s). https://doi.org/10.25258/ijddt.16.41s.84
Vancouver
Meenkire DHV, Makim DR. Ayurvedic Local and Oral Drug Delivery Therapies in Yonikandu (Atrophic Vaginitis): Evidence from Randomized Controlled Trials. International Journal of Drug Delivery Technology. 2026;16(41s). doi:10.25258/ijddt.16.41s.84
BibTeX
@article{Meenkire2026,
author = {Meenkire, Dr Hemalata V and Makim, Dr Rita},
title = {Ayurvedic Local and Oral Drug Delivery Therapies in Yonikandu (Atrophic Vaginitis): Evidence from Randomized Controlled Trials},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {41s},
doi = {10.25258/ijddt.16.41s.84}
}
EUVIMED